Sentinel Diagnostics Launches Two New Serological Tests To Quickly Assess The Immunoresponse To SARS-CoV-2

Sentinel Diagnostics

2021/5/5 12:13

AsiaNet  89354

 

MILAN, May 4, 2021 /PRNewswire=KYODO JBN/ --

 

To quickly assess the immune response to SARS-CoV-2 of patients and entire

communities, Sentinel Diagnostics - an Italian company focused for more than 35

years on the development and production of In Vitro Diagnostics for the most

advanced Clinical Chemistry, Immunochemistry and Molecular Diagnostics

platforms - announces the launch of two new serological tests for the detection

of total antibodies (IgA, IgG and IgM) to SARS-CoV-2 specific proteins in human

serum: COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab.

 

The application of these tests would help to identify those individuals who

have correctly developed antibodies after infection and/or vaccination,

supporting the understanding of the degree of diffusion of COVID-19 in the

community and the results of the efforts made by countries for vaccination

campaigns. "The spread of the SARS-CoV-2 pandemic and the current ongoing

vaccination campaigns have raised the need for quick evaluation of the

immunological status of individuals and communities to understand what measures

to adopt in order to avoid spreading of infection, but also to monitor the

immune response after vaccination," explains Marco Buonaguidi, Head of Sales

and Marketing. "We have developed our new quick solution that supports the

continuous monitoring of epidemic to ensure public health decisions delivering

fast results."

 

Both COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC Total Ab assays are In

Vitro Diagnostic tests, for quantitative and qualitative analysis with

immunoturbimetric method, designed to process hundreds of results in 1 hour and

thousands in a single day when used on our Sentinel SENTIFIT®270 Analyzer or

other automated analytical platforms. The first kit detects the total

antibodies against the Spike RBD S1 protein, while the second detects the

antibodies against Nucleocapsid (NC) protein.

 

The new Sentinel Diagnostics assays provide the first results in about 10

minutes. The use of Sentinel COVID-19 Anti-S1 Total Ab and COVID-19 Anti-NC

Total Ab would help distinguish vaccinated individuals from naturally infected

ones. The tests can be performed together on the same serum sample or

separately to better fit with laboratory needs.

 

For more information, visit www.sentineldiagnostics.com.

 

Logo - https://mma.prnewswire.com/media/1502740/Sentinel_Diagnostics_Logo.jpg

 

 

Source: Sentinel Diagnostics

  

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中